For research use only. Not for therapeutic Use.
Taprenepag isopropyl is a selective prostaglandin EP2 receptor agonist developed for the treatment of glaucoma and ocular hypertension. It works by increasing the outflow of aqueous humor, thereby reducing intraocular pressure, which is crucial in preventing optic nerve damage associated with glaucoma. Taprenepag isopropyl is applied as an eye drop, offering a localized treatment with the potential for fewer systemic side effects compared to other glaucoma medications. It represents a promising option for managing elevated intraocular pressure in patients.
| Catalog Number | I009704 |
| CAS Number | 1005549-94-9 |
| Synonyms | propan-2-yl 2-[3-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetate |
| Molecular Formula | C27H28N4O5S |
| Purity | ≥95% |
| InChI | InChI=1S/C27H28N4O5S/c1-21(2)36-27(32)20-35-25-7-3-6-23(16-25)19-30(37(33,34)26-8-4-13-28-17-26)18-22-9-11-24(12-10-22)31-15-5-14-29-31/h3-17,21H,18-20H2,1-2H3 |
| InChIKey | NVPXUFQLKWKBHK-UHFFFAOYSA-N |
| SMILES | CC(C)OC(=O)COC1=CC=CC(=C1)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4 |
